三個皮匠報告
政策庫
new
付費
搜索

HER2ADC治療乳腺癌競爭格局（III期以上）：DB-1303的全球臨床進展具有較強競爭優勢-行業數據

HER2ADC治療乳腺癌競爭格局（III期以上）：DB-1303的全球臨床進展具有較強競爭優勢
HER2ADC治療乳腺癌競爭格局（III期以上）：DB-1303的全球臨床進展具有較強競爭優勢
（DYNASTY-Breast01）（對照組為 T-DM1），有望在 2025H2 在中國遞交 HER+ BC 適應癥的 NDA、并于 2026H1 獲取完整 III 期臨床試驗數據讀出。
競爭格局 下載Excel 下載圖片 原圖定位
圖片屬性
圖片格式：PNG 圖片大?。?12KB 圖片尺寸：2303*1293
同報告圖片
 / 54
HER2ADC治療乳腺癌競爭格局（III期以上）：DB-1303的全球臨床進展具有較強競爭優勢_第1頁
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
HER2ADC治療乳腺癌競爭格局（III期以上）：DB-1303的全球臨床進展具有較強競爭優勢_第2頁
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
HER2ADC治療乳腺癌競爭格局（III期以上）：DB-1303的全球臨床進展具有較強競爭優勢_第3頁
HER2ADC治療乳腺癌競爭格局（III期以上）：DB-1303的全球臨床進展具有較強競爭優勢_第4頁
fCDlubTku70gfCDkuK3lm73vvIjljYHkur/nvo7lhYPvvIkgfCDnvo7lm73vvIjljYHkur/nvo7lhYPvvIkgfCDlhbbku5blnLDljLrvvIjljYHkur/nvo7lhYPvvIkgfAp8LS0tLS0tfC0tLS0tLS0tLS0tLS0tLS0tLXwtLS0tLS0tLS0tLS0tLS0tLS18LS0tLS0tLS0tLS0tLS0tLS0tfAp8IDIwMTggfCAwICAgICAgICAgICAgICAgIHwgMCAgICAgICAgICAgICAgICB8IDAgICAgICAgICAgICAgICAgfAp8IDIwMTkgfCAwICAgICAgICAgICAgICAgIHwgMCAgICAgICAgICAgICAgICB8IDAgICAgICAgICAgICAgICAgfAp8IDIwMjAgfCAwICAgICAgICAgICAgICAgIHwgMCAgICAgICAgICAgICAgICB8IDAgICAgICAgICAgICAgICAgfAp8IDIwMjEgfCAwICAgICAgICAgICAgICAgIHwgMCAgICAgICAgICAgICAgICB8IDAgICAgICAgICAgICAgICAgfAp8IDIwMjIgfCAwICAgICAgICAgICAgICAgIHwgMCAgICAgICAgICAgICAgICB8IDAgICAgICAgICAgICAgICAgfAp8IDIwMjMgfCAwICAgICAgICAgICAgICAgIHwgMCAgICAgICAgICAgICAgICB8IDAgICAgICAgICAgICAgICAgfAp8IDIwMjQgfCAwICAgICAgICAgICAgICAgIHwgMCAgICAgICAgICAgICAgICB8IDAgICAgICAgICAgICAgICAgfAp8IDIwMjUgfCAwICAgICAgICAgICAgICAgIHwgMCAgICAgICAgICAgICAgICB8IDAgICAgICAgICAgICAgICAgfAp8IDIwMjYgfCAwICAgICAgICAgICAgICAgIHwgMCAgICAgICAgICAgICAgICB8IDAgICAgICAgICAgICAgICAgfAp8IDIwMjcgfCAwICAgICAgICAgICAgICAgIHwgMCAgICAgICAgICAgICAgICB8IDAgICAgICAgICAgICAgICAgfAp8IDIwMjggfCAwICAgICAgICAgICAgICAgIHwgMCAgICAgICAgICAgICAgICB8IDAgICAgICAgICAgICAgICAgfAp8IDIwMjkgfCAwICAgICAgICAgICAgICAgIHwgMCAgICAgICAgICAgICAgICB8IDAgICAgICAgICAgICAgICAgfAp8IDIwMzAgfCAwICAgICAgICAgICAgICAgIHwgMCAgICAgICAgICAgICAgICB8IDAgICAgICAgICAgICAgICAgfAp8IDIwMzEgfCAwICAgICAgICAgICAgICAgIHwgMCAgICAgICAgICAgICAgICB8IDAgICAgICAgICAgICAgICAgfAp8IDIwMzIgfCAwICAgICAgICAgICAgICAgIHwgMCAgICAgICAgICAgICAgICB8IDAgICAgICAgICAgICAgICAgfAoK6LWE5paZ5p2l5rqQ77ya5YWs5Y+45oub6IKh6K+05piO5Lmm77yM5byX572X5pav54m55rKZ5Yip5paH77yM5Zu95rOw5rW36YCa6K+B5Yi456CU56m2
HER2ADC治療乳腺癌競爭格局（III期以上）：DB-1303的全球臨床進展具有較強競爭優勢_第5頁
5Lul5LiL5piv5o+Q5Y+W55qE5pWw5o2u5bm255Sf5oiQ55qE6KGo5qC877yM5Lul5Y+K6LWE5paZ5p2l5rqQ77yaCgp8IOW5tOS7vSB8IOmhueebruS4quaVsCB8CnwgLS0tLSB8IC0tLS0tLS0tIHwKfCAyMDE5IHwgNSAgICAgICAgfAp8IDIwMjAgfCAxMCAgICAgICB8CnwgMjAyMSB8IDI3ICAgICAgIHwKfCAyMDIyIHwgMzUgICAgICAgfAp8IDIwMjMgfCA0NCAgICAgICB8CnwgMjAyNCB8IDY4ICAgICAgIHwKCui1hOaWmeadpea6kO+8mkluc2lnaHQg5pWw5o2u5bqT77yM5Zu95rOw5rW36YCa6K+B5Yi456CU56m2
HER2ADC治療乳腺癌競爭格局（III期以上）：DB-1303的全球臨床進展具有較強競爭優勢_第6頁
5Lul5LiL5piv5o+Q5Y+W55qE5pWw5o2u5bm255Sf5oiQ55qE6KGo5qC877yM5Lul5Y+K6LWE5paZ5p2l5rqQ77yaCgp8IOW5tOS7vSB8IOmhueebruS4quaVsCB8CnwgLS0tLSB8IC0tLS0tLS0tIHwKfCAyMDE5IHwgMTggICAgICAgfAp8IDIwMjAgfCAyMCAgICAgICB8CnwgMjAyMSB8IDU4ICAgICAgIHwKfCAyMDIyIHwgNzggICAgICAgfAp8IDIwMjMgfCAxMTkgICAgICB8CnwgMjAyNCB8IDE3MyAgICAgIHwKCui1hOaWmeadpea6kO+8mkluc2lnaHQg5pWw5o2u5bqT77yM5Zu95rOw5rW36YCa6K+B5Yi456CU56m2
HER2ADC治療乳腺癌競爭格局（III期以上）：DB-1303的全球臨床進展具有較強競爭優勢_第7頁
fCAgfCDkuqTmmJPmgLvpop3vvIjljYPmlrnnvo7lhYPvvIkgfCDkuqTmmJPmgLvpop3ljZXnrJTlubPlnYfpop3vvIjnmb7kuIfnvo7lhYPvvIkgfAp8LS0tfC0tLXwtLS18Cnwg5YyW6I2vIHwgMzI4MjggfCA2NjEgfAp8IEFEQyB8IDE1MDk4IHwgMTkxMSB8Cnwg5Y2V5oqXIHwgMTEwMjAgfCA5MTEgfAp8IOaguOmFuCB8IDY2MTUgfCA5NzMgfAp8IOWPjOaKlyB8IDQ2ODAgfCA4MDcgfAp8IOe7huiDnuayu+eWlyB8IDQ0NzMgfCA3MTAgfAp8IOWfuuWboOayu+eWlyB8IDMzNjAgfCA2MjIgfAoK6LWE5paZ5p2l5rqQ77yaSW5zaWdodCDmlbDmja7lupPvvIzlm73ms7DmtbfpgJror4HliLjnoJTnqbY=
HER2ADC治療乳腺癌競爭格局（III期以上）：DB-1303的全球臨床進展具有較強競爭優勢_第8頁
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
HER2ADC治療乳腺癌競爭格局（III期以上）：DB-1303的全球臨床進展具有較強競爭優勢_第9頁
5Lul5LiL5piv5o+Q5Y+W55qE5pWw5o2u5bm255Sf5oiQ55qE6KGo5qC877yaCgp8IOiNr+eJqeexu+WeiyB8IOaVsOmHjyB8CnwgOi0tOiB8IDotLTogfAp8IEFEQyB8IDggfAp8IOWPjOaKlyB8IDQgfAp8IOaguOmFuCB8IDQgfAp8IEdMUC0xIHwgMiB8Cnwg5ZCI5oiQ6Ie05q27IHwgMiB8CnwgVExJMUHljZXmipcgfCAxIHwKfCDliIblrZDog7bpmY3op6PliYIgfCAxIHwKfCBDREsy5oqR5Yi25YmCIHwgMSB8CnwgQkNSLUFCTOaKkeWItuWJgiB8IDEgfAoK6LWE5paZ5p2l5rqQ77yaSW5zaWdodCDmlbDmja7lupPvvIzlm73ms7DmtbfpgJror4HliLjnoJTnqbY=
HER2ADC治療乳腺癌競爭格局（III期以上）：DB-1303的全球臨床進展具有較強競爭優勢_第10頁
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
HER2ADC治療乳腺癌競爭格局（III期以上）：DB-1303的全球臨床進展具有較強競爭優勢_第11頁
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
HER2ADC治療乳腺癌競爭格局（III期以上）：DB-1303的全球臨床進展具有較強競爭優勢_第12頁
HER2ADC治療乳腺癌競爭格局（III期以上）：DB-1303的全球臨床進展具有較強競爭優勢_第13頁
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
HER2ADC治療乳腺癌競爭格局（III期以上）：DB-1303的全球臨床進展具有較強競爭優勢_第14頁
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
HER2ADC治療乳腺癌競爭格局（III期以上）：DB-1303的全球臨床進展具有較強競爭優勢_第15頁
HER2ADC治療乳腺癌競爭格局（III期以上）：DB-1303的全球臨床進展具有較強競爭優勢_第16頁
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
HER2ADC治療乳腺癌競爭格局（III期以上）：DB-1303的全球臨床進展具有較強競爭優勢_第17頁
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
HER2ADC治療乳腺癌競爭格局（III期以上）：DB-1303的全球臨床進展具有較強競爭優勢_第18頁
HER2ADC治療乳腺癌競爭格局（III期以上）：DB-1303的全球臨床進展具有較強競爭優勢_第19頁
fCDml7bpl7QgICAgICAgfCDkuovku7YgICAgICAgICAgICAgICAgICAgICAgICAgfAp8LS0tLS0tLS0tLS0tfC0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLXwKfCAyMDIxLjUtMjAyMy41IHwg5Li05bqK5YmN5byA5Y+RICAgICAgICAgICAgICAgICAgICAgfAp8IDIwMjMuMyAgICAgfCDkuI5CaW9OVGVjaOetvuiuouiuuOWPr+WQiOS9nOWNj+iuriAgICAgfAp8IDIwMjMuNSAgICAgfCDlkJFGREHpgJLkuqRJSWxsYSBJTkTnlLPor7cgICAgICAgIHwKfCAyMDIzLjUgICAgIHwgRkRB5om55YeGSUlsbGHmnJ9JTkQgICAgICAgICAgICAgfAp8IDIwMjMuNiAgICAgfCDlkJFOTVBB6YCS5LqkSUlsbGHmnJ9JTkTnlLPor7cgICAgICB8CnwgMjAyMy44ICAgICB8IE5NUEHmibnlh4ZJSWxsYeacn0lORCAgICAgICAgICAgIHwKfCAyMDIzLjkgICAgIHwg5pma5pyf5oiW6L2s56e75oCn5a6e5L2T55ikSUlsbGHmnJ/kuLTluorlkK/liqggfAp8IDIwMjQuMyAgICAgfCBJ5pyf5a6M5oiQICAgICAgICAgICAgICAgICAgICAgICB8CnwgMjAyNC42ICAgICB8IOiOt0ZEQeW/q+mAn+mAmumBk+iupOWumu+8jOeUqOS6juaZmuacn0NSUEPmsrvnlpcgfAp8IDIwMjQuNyAgICAgfCDojrdGREHlraTlhL/oja/otYTmoLzorqTlrprvvIznlKjkuo5FU0ND5rK755aXIHwKfCAyMDI0LjggICAgIHwg6I63RkRB5a2k5YS/6I2v6LWE5qC86K6k5a6a77yM55So5LqOU0NMQ+ayu+eWlyB8CnwgMjAyNC4xMiAgICB8IElJSWxsYeacn+aVsOaNruivu+WHuuW5tuWcqEVTTU8gQXNpYei/m+ihjOWPo+WktOaKpeWRiiB8CnwgMjAyNS4zICAgICB8IOiBlOWQiEJOVDMyNyAoUEQxL1ZFR0Yp5rK755aX5pma5pyf6IK655mMSUlJbGxh5pyf5ZCv5YqoIHwKfCAyMDI2ICAgICAgIHwgSUlJbGxh5pyf5Li05bqK5a6M5oiQICAgICAgICAgICAgICB8CgoK6LWE5paZ5p2l5rqQ77ya5YWs5Y+45oub6IKh5Lmm77yM5Zu95rOw5rW36YCa6K+B5Yi456CU56m2
HER2ADC治療乳腺癌競爭格局（III期以上）：DB-1303的全球臨床進展具有較強競爭優勢_第20頁
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
HER2ADC治療乳腺癌競爭格局（III期以上）：DB-1303的全球臨床進展具有較強競爭優勢_第21頁
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
HER2ADC治療乳腺癌競爭格局（III期以上）：DB-1303的全球臨床進展具有較強競爭優勢_第22頁
HER2ADC治療乳腺癌競爭格局（III期以上）：DB-1303的全球臨床進展具有較強競爭優勢_第23頁
HER2ADC治療乳腺癌競爭格局（III期以上）：DB-1303的全球臨床進展具有較強競爭優勢_第24頁
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
HER2ADC治療乳腺癌競爭格局（III期以上）：DB-1303的全球臨床進展具有較強競爭優勢_第25頁
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
HER2ADC治療乳腺癌競爭格局（III期以上）：DB-1303的全球臨床進展具有較強競爭優勢_第26頁
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
HER2ADC治療乳腺癌競爭格局（III期以上）：DB-1303的全球臨床進展具有較強競爭優勢_第27頁
5aW955qE77yM5Lul5LiL5piv6K+l5Zu+54mH5Lit55qE5pWw5o2u5Lul5Y+K5a+55bqU55qE6KGo5qC85ZKM6LWE5paZ5p2l5rqQ77yaCgp8IOayu+eWl+i3r+W+hCB8IOiNr+eJqS/nlpfms5UgfAp8IC0tLSB8IC0tLSB8Cnwg5pyq5pu+5o6l5Y+X5aSa6KW/5LuW6LWb5ZKM5pyq5o6l5Y+X5paw5Z6L5r+A57Sg55aX5rOVIHwg6Zi/5q+U54m56b6ZL+azvOWwvOadvum+mS/mganmiY7ljaLog7o8YnI+6ZWtLTIzM++8iOS8tOeXh+eKtumqqOi9rOenu+aCo+iAhe+8iTxicj7lsLzmi4nluJXlsLwv5aWl5ouJ5biV5YipK+mYv+avlOeJuem+me+8iEJSQ0HnqoHlj5jmgqPogIXvvIk8YnI+5biV5Y2a5Yip54+g5Y2V5oqX77yITVNJLUgvZE1NUuaCo+iAhe+8iTxicj5TaXB1bGV1Y2VsLVQ8YnI+5LuW5ouJ5ZSR5biV5YipK+aBqeaJjuWNouiDuu+8iEhSUueqgeWPmOaCo+iAhe+8iSB8Cnwg5pyq5o6l5Y+X5aSa6KW/5LuW6LWb5ZKM5pei5b6A5o6l5Y+X5paw5Z6L5r+A57Sg55aX5rOV5bm26L+b5bGVIHwg5aSa6KW/5LuW6LWbPGJyPuWlpeaLieW4leWIqS/oiqbljaHluJXlsLw8YnI+5Y2h5be05LuW6LWbK+WNoemTgjxicj7lsLzmi4nluJXlsLwr6Zi/5q+U54m56b6Z77yIQlJDQeeqgeWPmOaCo+iAhe+8iTxicj7lpaXmi4nluJXliKnvvIhIUlLvvIjpnZ5CUkNBMS8y77yJ5oKj6ICF77yJPGJyPuW4leWNmuWIqeePoOWNleaKl++8iE1TSS1IL2RNTVLmgqPogIXvvIk8YnI+6ZWtLTIzM++8iOS8tOeXh+eKtumqqOi9rOenu+aCo+iAhe+8iTxicj5TaXB1bGV1Y2VsLVQgfAp8IOaXouW+gOaOpeWPl+Wkmuilv+S7lui1m+W5tui/m+WxleWSjOacquaOpeWPl+aWsOWei+a/gOe0oOeWl+azlSB8IOmYv+avlOeJuem+mS/ms7zlsLzmnb7pvpkv5oGp5omO5Y2i6IO6PGJyPuWNoeW3tOS7lui1myvljaHpk4I8YnI+57Gz5omY6JK96YaM77yI5YW25LuW55aX5rOV5LiN6ICQ5Y+X5pyJ55eH54q25oKj6ICF6Kej5pWR77yJPGJyPuWwvOaLieW4leWwvC/lpaXmi4nluJXliKkr6Zi/5q+U54m56b6Z77yIQlJDQeeqgeWPmOaCo+iAhe+8iTxicj7luJXljZrliKnnj6DljZXmipfvvIhNU0ktSC9kTU1S5oKj6ICF77yJPGJyPumVrS0yMzPvvIjkvLTnl4fnirbpqqjovaznp7vmgqPogIXvvIk8YnI+U2lwdWxldWNlbC1UPGJyPuS7luaLieWUkeW4leWIqSvmganmiY7ljaLog7rvvIhIUlLnqoHlj5jmgqPogIXvvIkgfAp8IOaXouW+gOaOpeWPl+Wkmuilv+S7lui1m+WSjOaWsOWei+a/gOe0oOeWl+azleW5tui/m+WxlSB8IOWNoeW3tOS7lui1my/lpJropb/ku5botZvnu6fnu63msrvnlpc8YnI+5Y2h5be05LuW6LWbK+WNoemTgjxicj5MdS0xNzctUFNNQS02MTfvvIhQU01B6Ziz5oCn6L2s56e75oCn5oKj6ICF77yJPGJyPuexs+aJmOiSvemGjO+8iOWFtuS7lueWl+azleS4jeiAkOWPl+acieeXh+eKtuaCo+iAheino+aVke+8iTxicj7lpaXmi4nluJXliKnvvIhIUlLmgqPogIXvvIk8YnI+5biV5Y2a5Yip54+g5Y2V5oqX77yITVNJLUgvZE1NUuaIllRNQuKJpTEwbXV0L01i5oKj6ICF77yJPGJyPumVrS0yMzPvvIjkvLTnl4fnirbpqqjovaznp7vmgqPogIXvvIk8YnI+6Iqm5Y2h5biV5bC877yIQlJDQeeqgeWPmOaCo+iAhe+8iSB8CgrotYTmlpnmnaXmupDvvJpOQ0NO77yM5Zu95rOw5rW36YCa6K+B5Yi456CU56m2
HER2ADC治療乳腺癌競爭格局（III期以上）：DB-1303的全球臨床進展具有較強競爭優勢_第28頁
HER2ADC治療乳腺癌競爭格局（III期以上）：DB-1303的全球臨床進展具有較強競爭優勢_第29頁
HER2ADC治療乳腺癌競爭格局（III期以上）：DB-1303的全球臨床進展具有較強競爭優勢_第30頁
HER2ADC治療乳腺癌競爭格局（III期以上）：DB-1303的全球臨床進展具有較強競爭優勢_第31頁
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
HER2ADC治療乳腺癌競爭格局（III期以上）：DB-1303的全球臨床進展具有較強競爭優勢_第32頁
HER2ADC治療乳腺癌競爭格局（III期以上）：DB-1303的全球臨床進展具有較強競爭優勢_第33頁
HER2ADC治療乳腺癌競爭格局（III期以上）：DB-1303的全球臨床進展具有較強競爭優勢_第34頁
HER2ADC治療乳腺癌競爭格局（III期以上）：DB-1303的全球臨床進展具有較強競爭優勢_第35頁
fCDkuovku7YgfCDml7bpl7QgfAp8LS0tLS0tLXwtLS0tLS18CnwgRkRB5om55YeGSUlh5pyfSU5EIHwgMjAyMy4zIHwKfCBOTVBB5om55YeGSUlh5pyfSU5EIHwgMjAyMy41IHwKfCBJ5pyf5Yid5q2l57uT5p6c6K+75Ye6IHwgMjAyNC41IHwKfCBJSWHmnJ/mianlop7pmJ/liJfkuK3mnJ/mlbDmja7miqvpnLIgfCAyMDI1SDIgfAoK6LWE5paZ5p2l5rqQ77ya5YWs5Y+45oub6IKh5Lmm77yM5Zu95rOw5rW36YCa6K+B5Yi456CU56m2
HER2ADC治療乳腺癌競爭格局（III期以上）：DB-1303的全球臨床進展具有較強競爭優勢_第36頁
HER2ADC治療乳腺癌競爭格局（III期以上）：DB-1303的全球臨床進展具有較強競爭優勢_第37頁
HER2ADC治療乳腺癌競爭格局（III期以上）：DB-1303的全球臨床進展具有較強競爭優勢_第38頁
fCDlubTku70gfCDph5Hono3otJ/lgLrlhazlhYHku7flgLzlj5jliqjlr7zoh7TnmoTmjIHnu63kuo/mjZ/vvIjkur/lhYPvvIkgfAp8LS0tLS0tfC0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tfAp8IDIwMjIgfCAtMy44NyAgICAgICAgICAgICAgICAgICAgICAgICAgfAp8IDIwMjMgfCAtMy41OCAgICAgICAgICAgICAgICAgICAgICAgICAgfAp8IDIwMjQgfCAtMTAuNTAgICAgICAgICAgICAgICAgICAgICAgICAgfAoK6LWE5paZ5p2l5rqQ77yaV2luZO+8jOWbveazsOa1t+mAmuivgeWIuOeglOeptg==
HER2ADC治療乳腺癌競爭格局（III期以上）：DB-1303的全球臨床進展具有較強競爭優勢_第39頁
fCDml6XmnJ8gfCDnoJTlj5HmlK/lh7rvvIjkur/lhYPvvIkgfAp8LS0tLS0tfC0tLS0tLS0tLS0tLS0tLS18CnwgMjAyMiB8IC0zLjQwICAgICAgICAgIHwKfCAyMDIzIHwgLTUuNTkgICAgICAgICAgfAp8IDIwMjQgfCAtOC4zNyAgICAgICAgICB8CgoK6LWE5paZ5p2l5rqQ77yaV2luZO+8jOWbveazsOa1t+mAmuivgeWIuOeglOeptg==
HER2ADC治療乳腺癌競爭格局（III期以上）：DB-1303的全球臨床進展具有較強競爭優勢_第40頁
5Lul5LiL5piv5o+Q5Y+W55qE5pWw5o2u5bm255Sf5oiQ55qE6KGo5qC877yM5Lul5Y+K6LWE5paZ5p2l5rqQ77yaCgp8IOW5tOS7vSB8IOihjeeUn+mHkeiejei0n+WAuuWFrOWFgeS7t+WAvOWPmOWKqO+8iOS6v+WFg++8iSB8CnwtLS0tLS18LS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS18CnwgMjAyMiB8IC0wLjIyICAgICAgICAgICAgICAgICAgICAgICB8CnwgMjAyMyB8IC0xMC4xOCAgICAgICAgICAgICAgICAgICAgICB8CnwgMjAyNCB8IC04LjczICAgICAgICAgICAgICAgICAgICAgICB8CgrotYTmlpnmnaXmupDvvJpXaW5k77yM5Zu95rOw5rW36YCa6K+B5Yi456CU56m2
HER2ADC治療乳腺癌競爭格局（III期以上）：DB-1303的全球臨床進展具有較強競爭優勢_第41頁
HER2ADC治療乳腺癌競爭格局（III期以上）：DB-1303的全球臨床進展具有較強競爭優勢_第42頁
HER2ADC治療乳腺癌競爭格局（III期以上）：DB-1303的全球臨床進展具有較強競爭優勢_第43頁
HER2ADC治療乳腺癌競爭格局（III期以上）：DB-1303的全球臨床進展具有較強競爭優勢_第44頁
HER2ADC治療乳腺癌競爭格局（III期以上）：DB-1303的全球臨床進展具有較強競爭優勢_第45頁
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
HER2ADC治療乳腺癌競爭格局（III期以上）：DB-1303的全球臨床進展具有較強競爭優勢_第46頁
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
HER2ADC治療乳腺癌競爭格局（III期以上）：DB-1303的全球臨床進展具有較強競爭優勢_第47頁
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
HER2ADC治療乳腺癌競爭格局（III期以上）：DB-1303的全球臨床進展具有較強競爭優勢_第48頁
fCDljoLllYYgICB8IE1TRCAgIHwg572X5rCPICAgfCDnrKzkuIDkuInlhbEv6Zi/5pav5Yip5bq3IHwg5pig5oGp55Sf54mpL0Jpb05UZWNoIHwg6Zi/5pav5Yip5bq3IHwg56ys5LiA5LiJ5YWxL+mYv+aWr+WIqeW6tyB8IOenkeS8puWNmuazsC9NU0QgfAp8LS0tLS0tLS18LS0tLS0tLS18LS0tLS0tLS18LS0tLS0tLS0tLS0tLS0tLS0tfC0tLS0tLS0tLS0tLS0tLS0tLXwtLS0tLS0tLXwtLS0tLS0tLS0tLS0tLS0tLS18LS0tLS0tLS0tLS0tfAp8IOS9nOeUqOacuueQhiB8IFBELTEg5Y2V5oqXICtWRUdG5oqR5Yi25YmCIHwgVkVHRiDljZXmipcgfCBIRVIyIEFEQyB8IEhFUjIgQURDIHwgQjctSDQgQURDIHwgVFJPUDIgQURDIHwgVFJPUDIgQURDIHwKfCDkurrmlbAgICAgfCA0MTEgICAgfCA1MiAgICAgfCA0MCAgICAgICAgICAgICAgIHwgMTcgICAgICAgICAgICAgICB8IDUyICAgICB8IDQwICAgICAgICAgICAgICAgfCA0NCAgICAgICAgIHwKfCDmgqPogIXln7rnur8gfCDmlL7nlpfnu4/ljoYgNDkuMiUvNTguNSUgICB8IOaXouW+gCAxIOe6vyA2My41JSB8IOS4reS9jeaXouW+gOayu+eWl+S6jOe6vyBIRVIyIElIQyAyLzMrIHwg5Lit5L2N5pei5b6A5rK755aX5LqM57q/IElIQyAxLzIvMyvmiJYgSVNIKyB8IOS4reS9jeaXouW+gOayu+eWl+S4gOe6vyBCNy1INCDooajovr4gNTcuNSUvNTUuMCUgfCDkuK3kvY3ml6LlvoDmsrvnlpfkuIDnur8gfCDml6LlvoAgMSDnur8gNDcuNyUg5pei5b6A4omlMiDnur8gNTIuMyUgVFJPUDIg6auY6KGo6L6+IDI3LjMlIHwKfCDliYLph48gICAgfCAyMDBtZyAgfCAxNSBtZy9rZyB8IDUuNCBtZy9rZyAgICAgICAgfCA3LzggbWcva2cgICAgICAgIHwgMi4wLzIuNCBtZy9rZyB8IDYgbWcva2cgICAgICAgICAgfCA1IG1nL2tnICAgIHwKfCBPUlIgICAgfCAzMy44JSAgfCAxMy41JSAgfCA1MCUgSEVSMiBJSEMgMysgODQuNiUgSEVSMiBJSEMgMisgNDcuMSUgfCA1OC44JSAoY09SUj0zNS4zJSkgNyBtZy9rZyA1MC4wJSA4IG1nL2tnIDYxLjUlIHwgMi4wIG1nL2tnOiAzNC42JSAyLjQgbWcva2c6IDM4LjUlIHwgMjcuNTAlIHwgMzQuMSUgKGNPUlI9MjcuMyUpIFRST1AyIOmrmOihqOi+vu+8mjQxLjclIHwKfCBEQ1IgICAgfCA3Mi4zJSAgfCA0Ni42JSAgfCA5NC4xJSAgICAgICAgICAgIHwgNyBtZy9rZyAxMDAlIDggbWcva2cgOTIuMyUgfCAyLjAgbWcva2c6IDgwLjglIDIuNCBtZy9rZzogODQuNiUgfCA5MS40JSB8IDc1LjAlIHwKfCDiiaUzIOe6pyBURUFFIHwgOTAlICAgIHwgNzQlICAgIHwgMzEuMiUgICAgICAgICAgICB8ICAgICAgICAgICAgICAgICAgfCAgICAgICAgICB8ICAgICAgICAgICAgICAgICAgfCAgICAgICAgICAgIHwKfCDiiaUzIOe6pyBUUkFFIHwgNzklICAgIHwgNjAlICAgIHwgNDAuOCUgICAgICAgICAgICB8IDE1LjYlICAgICAgICAgICAgfCAyLjAgbWcva2c6IDQwJSAyLjQgbWcva2c6IDM0LjMlIHwgNDIuNSUgfCA3Mi43JSB8CnwgVEVBRSDoh7TlgZzoja8gfCBLIOiNryAxOC43JSDku5HkvJDmm7/lsLwgMzAuOCUgfCA4LjAlICAgIHwgOC42JSAgICAgICAgICAgIHwgMCAgICAgICAgICAgICAgICB8ICAgICAgICAgIHwgMjcuNSUgfCAyLjMlIHwKfCDpl7TotKjmgKfogrrngo4gfCAxMC41JSDiiaQyIOe6pyA5LjAlIDUg57qnIDEuMSUgfCAgICAgICAgICB8ICAgICAgICAgICAgICAgICB8ICAgICAgICAgICAgICAgICAgfCAgICAgICAgICB8ICAgICAgIHwgICAgICB8CgrotYTmlpnmnaXmupDvvJpJbnNpZ2h0IOaVsOaNruW6k++8jOOAikxlbnZhdGluaWIgUGx1cyBQZW1icm9saXp1bWFiIGluIFByZXZpb3VzbHkgVHJlYXRlZCBBZHZhbmNlZCBFbmRvbWV0cmlhbCBDYW5jZXI6IFVwZGF0ZWQgRWZmaWNhY3kgYW5k
HER2ADC治療乳腺癌競爭格局（III期以上）：DB-1303的全球臨床進展具有較強競爭優勢_第49頁
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
HER2ADC治療乳腺癌競爭格局（III期以上）：DB-1303的全球臨床進展具有較強競爭優勢_第50頁
HER2ADC治療乳腺癌競爭格局（III期以上）：DB-1303的全球臨床進展具有較強競爭優勢_第51頁
HER2ADC治療乳腺癌競爭格局（III期以上）：DB-1303的全球臨床進展具有較強競爭優勢_第52頁
HER2ADC治療乳腺癌競爭格局（III期以上）：DB-1303的全球臨床進展具有較強競爭優勢_第53頁
HER2ADC治療乳腺癌競爭格局（III期以上）：DB-1303的全球臨床進展具有較強競爭優勢_第54頁
HER2ADC治療乳腺癌競爭格局（III期以上）：DB-1303的全球臨床進展具有較強競爭優勢_第55頁
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
所屬報告： 映恩生物~B-港股公司首次覆蓋報告：創新驅動ADC新秀邁向全球舞臺-250420（43頁）.pdf
打包全文圖表

相關數據

最新數據
聯系我們
  • 0731-84720580
  • sgpjbg002
  • 工作日 9:30 - 18:00
關于我們
侵權處理
關于我們

三個皮匠報告專業的行業報告下載站，每日更新，歡迎大家關注！

copyright@2008-2013 長沙景略智創信息技術有限公司版權所有
網站備案/許可證號：湘B2-20190120

客服
商務合作
小程序
服務號
折疊
午夜网日韩中文字幕,日韩Av中文字幕久久,亚洲中文字幕在线一区二区,最新中文字幕在线视频网站